: Cassava Sciences stock price target cut to $28 from $44 at B. Riley

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Cassava Sciences Inc.

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply